Related Experiment Videos
Transthyretin mutations in hyperthyroxinemia and amyloid diseases
1Amyloid Unit, Institute for Molecular and Cellular Biology and Instituto de Ciências Biomédicas, Universidade do Porto, Porto, Portugal. mjsaraiv@ibmc.up.pt
Human Mutation
|June 1, 2001
Summary
Over 80 transthyretin (TTR) mutations cause disease, primarily through amyloid deposition affecting nerves and the heart. Some TTR mutations are non-amyloidogenic, causing hyperthyroxinemia, and can offer protection against pathogenic mutations.
Area of Science:
- Genetics and Molecular Biology
- Biochemistry
- Medical Science
Background:
- Transthyretin (TTR) mutations are linked to various diseases.
- Over 80 disease-causing TTR mutations have been identified.
- Most TTR mutations cause amyloid deposition in peripheral nerves and the heart.
Purpose of the Study:
- To review current transthyretin (TTR) mutations.
- To discuss the significance of TTR mutations in disease.
- To highlight non-amyloidogenic TTR mutations and their effects.
Main Methods:
- Literature review of TTR mutations.
- Analysis of genetic inheritance patterns (autosomal dominant).
- Classification of TTR mutations based on disease mechanism (amyloidogenic vs. non-amyloidogenic).
Main Results:
- The majority of TTR mutations are autosomal dominant and lead to amyloidosis.
- A subset of TTR mutations are non-amyloidogenic, causing hyperthyroxinemia.
- Compound heterozygosity for TTR mutations can result in a protective effect of non-pathogenic over pathogenic mutations.
Conclusions:
- TTR mutations have diverse clinical manifestations, including amyloidosis and altered thyroid hormone transport.
- Understanding TTR mutation types is crucial for diagnosing and managing related diseases.
- The interplay between different TTR mutations can influence clinical outcomes.